Abstract
Acute and chronic effects of the insulinotropic drug nateglinide upon insulin release were examined in the BRIN‐BD11 cell line. Nateglinide (10–400 μM) stimulated a concentration‐dependent increase (PPμM nateglinide was increased at 30 mM (PμM) evoked KATP channel‐independent insulin secretion (PPPμM nateglinide abolished the acute insulinotropic effects of 200 μM nateglinide, tolbutamide or glibenclamide, but had no effect upon the insulinotropic effect of 200 μM efaroxan. While 18 h exposure to 100 μM nateglinide did not affect basal insulin release or insulin release in the presence of 16.7 mM glucose, 25 μM forskolin or 10 nM PMA, significant inhibition of the insulinotropic effects of 20 mM leucine and 20 mM arginine were observed. These data show that nateglinide stimulates both KATP channel‐dependent and‐independent insulin secretion. The maintained insulinotropic effects of this drug with increasing glucose concentrations support the antihyperglycaemic actions of nateglinide in Type II diabetes. Studies of the long‐term effects of nateglinide indicate that nateglinide shares signalling pathways with sulphonylureas, but not the imidazoline efaroxan. This may be significant when considering a nateglinide treatment regimen, particularly in patients previously treated with sulphonylurea. British Journal of Pharmacology (2004) 142, 367–373. doi:10.1038/sj.bjp.0705766

This publication has 50 references indexed in Scilit: